Registration Dossier

Administrative data

Link to relevant study record(s)

Description of key information

Key value for chemical safety assessment

Additional information

Assessment of the Toxicokinetic Behaviour for Oxooel 13 (CAS-No. 68526-91-0)

 

There were no studies available in which the toxicokinetic properties of Oxooel 13 were investigated.

 

Oxooel 13 (molecular weight of 198.35 g/mol) is a clear colourless liquid, which is soluble in water(measured water solubility: 10 - 14 mg/l at 20 °C (BASF SE, 2009); see “water solubility”).The estimated log Pow is 4.9 at 20 °C (BASF SE, 2009; see “partition coefficient”), indicating that a general accumulation of Oxooel 13 is possible.

Due to the physico-chemical properties, a general accumulation of the test item might be possible.

 

Absorption

 

In an acute oral and dermal toxicity study, rats were once administered Oxooel 13. In both studies neither mortalities nor signs of systemic toxicity were observed in doses of 2000 mg/kg bw and higher (BASF AG, 1982; see “acute oral toxicity”; BASF SE, 2009; see “acute dermal toxicity”), indicating primarily a low acute toxicity.

In a subacute study in rats signs of general systemic toxicity (hematologic changes) were observed at a dose level of 1000 mg/kg bw/d (BASF SE, 2010).Therefore, bioavailability of Oxooel 13 after oral administration is indicated.

Additionally, due to the physico-chemical properties described above (molecular weight, water solubility, logPow), an uptake via the GI tract and a dermal uptake is possible.

Oxooel 13 has a comparably low vapour pressure of 0.3 hPa at 20°C (BASF SE, 2009, see “vapour pressure”). Therefore, exposure of the test item via the inhalative route is not assumed.

Due to the experimental low acute oral and dermal toxicity, no quantitative assessment of the absorption potential of Oxooel 13 in humans can be made.

 

Metabolism

 

The signs of general systemic toxicity (hematologic changes) observed at a dose level of 1000 mg/kg bw/d in the subacute study in rats (BASF SE, 2010) suggests bioavailability of Oxooel 13 after oral administration.

The test item shows skin sensitisation in the LLNA.This implies protein binding. But information about potential metabolites is not available.

Studies on genotoxicity (Ames-Test, HPRT-Test) gave no indication for toxic metabolism.

 

Excretion

 

Given that there is no information about potential metabolites available, it can only be assumed from the physico-chemical properties that Oxooel 13 is possible to accumulate in the fatty tissue.